ABSI Absci | $8.24
-4.7% | 9/9/2026 | | Initiated Coverage | | Outperform | 00.00% | View details for Lifesci Capital rating of Absci (NASDAQ:ABSI) on 9/9/2026 |
TCRX TScan Therapeutics | $0.32
-3.7% | 9/2/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of TScan Therapeutics (NASDAQ:TCRX) on 9/2/2026 |
VTVT vTv Therapeutics | $31.86
-4.3% | 9/2/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of vTv Therapeutics (NASDAQ:VTVT) on 9/2/2026 |
BLSM BlossomHill Therapeutics | $21.51
-2.2% | 9/1/2026 | | Initiated Coverage | $32.00 | Outperform | 00.00% | View details for Lifesci Capital rating of BlossomHill Therapeutics (NASDAQ:BLSM) on 9/1/2026 |
ATTO Attovia Therapeutics | $22.53
-1.4% | 8/31/2026 | | Initiated Coverage | $45.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Attovia Therapeutics (NASDAQ:ATTO) on 8/31/2026 |
APMD Apnimed | $26.80
-4.6% | 8/25/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Apnimed (NASDAQ:APMD) on 8/25/2026 |
OBX Obsidian Therapeutics | $17.16
-8.1% | 8/18/2026 | | Initiated Coverage | $43.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Obsidian Therapeutics (NASDAQ:OBX) on 8/18/2026 |
LQDA Liquidia | $67.85
-1.8% | 8/12/2026 | | Downgrade | $90.00 | Outperform ➝ Hold | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 8/12/2026 |
SION Sionna Therapeutics | $7.62
+1.9% | 8/10/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 8/10/2026 |
CNTX Context Therapeutics | $0.37
-1.0% | 8/6/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Context Therapeutics (NASDAQ:CNTX) on 8/6/2026 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
ELOX Eloxx Pharmaceuticals | $16.28
-1.8% | 7/22/2026 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Eloxx Pharmaceuticals (NASDAQ:ELOX) on 7/22/2026 |
CRNX Crinetics Pharmaceuticals | $84.95
| 7/7/2026 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/7/2026 |
PBLS Parabilis Medicines | $36.32
-6.3% | 7/6/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Parabilis Medicines (NASDAQ:PBLS) on 7/6/2026 |
QNCX Quince Therapeutics | $28.96
-4.5% | 6/29/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Quince Therapeutics (NASDAQ:QNCX) on 6/29/2026 |
IMMX Immix Biopharma | $12.70
+3.2% | 6/17/2026 | | Initiated Coverage | $19.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Immix Biopharma (NASDAQ:IMMX) on 6/17/2026 |
MANE Veradermics | $98.21
-1.5% | 6/16/2026 | | Initiated Coverage | $135.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Veradermics (NYSE:MANE) on 6/16/2026 |
RCUS Arcus Biosciences | $25.95
-8.9% | 6/4/2026 | | Initiated Coverage | $46.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Arcus Biosciences (NYSE:RCUS) on 6/4/2026 |
ACRS Aclaris Therapeutics | $5.51
-0.9% | 6/2/2026 | | Initiated Coverage | $13.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/2/2026 |
ACRS Aclaris Therapeutics | $5.51
-0.9% | 6/1/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aclaris Therapeutics (NASDAQ:ACRS) on 6/1/2026 |
KRRO Korro Bio | $13.06
+1.0% | 5/29/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Korro Bio (NASDAQ:KRRO) on 5/29/2026 |
SLGL Sol-Gel Technologies | $66.79
-3.5% | 5/15/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sol-Gel Technologies (NASDAQ:SLGL) on 5/15/2026 |
MPLT Maplight Therapeutics | $13.78
+0.5% | 5/14/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Maplight Therapeutics (NASDAQ:MPLT) on 5/14/2026 |
IMUX Immunic | $11.84
-2.9% | 5/4/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Immunic (NASDAQ:IMUX) on 5/4/2026 |
STRO Sutro Biopharma | $17.83
-2.8% | 5/1/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sutro Biopharma (NASDAQ:STRO) on 5/1/2026 |
INBX Inhibrx Biosciences | $111.42
-1.3% | 4/24/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibrx Biosciences (NASDAQ:INBX) on 4/24/2026 |
MBX MBX Biosciences | $60.94
-3.1% | 3/31/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of MBX Biosciences (NASDAQ:MBX) on 3/31/2026 |
MREO Mereo BioPharma Group | $0.24
+0.9% | 3/19/2026 | | Upgrade | | Hold | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 3/19/2026 |
TARS Tarsus Pharmaceuticals | $81.12
-2.0% | 3/16/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tarsus Pharmaceuticals (NASDAQ:TARS) on 3/16/2026 |
TENX Tenax Therapeutics | $1.95
-8.5% | 3/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tenax Therapeutics (NASDAQ:TENX) on 3/12/2026 |
JBIO Jade Biosciences | $19.14
+0.4% | 3/6/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Jade Biosciences (NASDAQ:JBIO) on 3/6/2026 |
LQDA Liquidia | $67.85
-1.8% | 3/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 3/5/2026 |
TNYA Tenaya Therapeutics | $0.65
-1.8% | 3/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/5/2026 |
PRME Prime Medicine | $3.35
-3.5% | 3/2/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 3/2/2026 |
RCKT Rocket Pharmaceuticals | $3.48
-4.1% | 2/26/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 2/26/2026 |
SION Sionna Therapeutics | $7.62
+1.9% | 2/25/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 2/25/2026 |
LRMR Larimar Therapeutics | $3.85
-0.5% | 2/24/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Larimar Therapeutics (NASDAQ:LRMR) on 2/24/2026 |
CNTX Context Therapeutics | $0.37
-1.0% | 2/23/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Context Therapeutics (NASDAQ:CNTX) on 2/23/2026 |
IKT Inhibikase Therapeutics | $2.33
-3.3% | 2/23/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 2/23/2026 |
CRNX Crinetics Pharmaceuticals | $84.95
| 2/13/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 2/13/2026 |
CMPS Compass Pathways | $14.22
-6.3% | 2/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Compass Pathways (NASDAQ:CMPS) on 2/12/2026 |
Here’s the stock symbol I’ve promised (Ad) Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better.
This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. Get the stock name and ticker symbol free of charge today |
IRD Opus Genetics | $6.07
+5.9% | 2/12/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Opus Genetics (NASDAQ:IRD) on 2/12/2026 |
TECX Tectonic Therapeutic | $28.61
-6.1% | 2/5/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 2/5/2026 |
DMRA Damora Therapeutics, Inc. Common Stock | $26.84
+2.2% | 2/2/2026 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) on 2/2/2026 |
NGNE Neurogene | $36.12
-4.6% | 1/26/2026 | | Initiated Coverage | $50.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Neurogene (NASDAQ:NGNE) on 1/26/2026 |
MREO Mereo BioPharma Group | $0.24
+0.9% | 12/29/2025 | | Downgrade | | Outperform ➝ Hold | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/29/2025 |
PRME Prime Medicine | $3.35
-3.5% | 12/23/2025 | | Initiated Coverage | $6.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025 |
PRME Prime Medicine | $3.35
-3.5% | 12/23/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Prime Medicine (NASDAQ:PRME) on 12/23/2025 |
SION Sionna Therapeutics | $7.62
+1.9% | 12/23/2025 | | Initiated Coverage | $60.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Sionna Therapeutics (NASDAQ:SION) on 12/23/2025 |
OVID Ovid Therapeutics | $2.63
-2.6% | 12/22/2025 | | Initiated Coverage | $4.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Ovid Therapeutics (NASDAQ:OVID) on 12/22/2025 |
IBIO iBio | $1.23
-2.8% | 12/18/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of iBio (NASDAQ:IBIO) on 12/18/2025 |
MAZE Maze Therapeutics | $24.82
+1.0% | 12/18/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Maze Therapeutics (NASDAQ:MAZE) on 12/18/2025 |
EPRX Eupraxia Pharmaceuticals | $8.02
-0.7% | 12/11/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Eupraxia Pharmaceuticals (NASDAQ:EPRX) on 12/11/2025 |
OCS Oculis | $11.31
-1.4% | 12/3/2025 | | Initiated Coverage | $55.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Oculis (NASDAQ:OCS) on 12/3/2025 |
UPB Upstream Bio | $5.75
-3.5% | 12/2/2025 | | Initiated Coverage | $43.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Upstream Bio (NASDAQ:UPB) on 12/2/2025 |
IKT Inhibikase Therapeutics | $2.33
-3.3% | 12/1/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Inhibikase Therapeutics (NASDAQ:IKT) on 12/1/2025 |
ADAG Adagene | $3.31
+1.2% | 11/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Adagene (NASDAQ:ADAG) on 11/14/2025 |
KLC KinderCare Learning Companies | $2.52
-1.0% | 11/13/2025 | | Reiterated Rating | | Market Perform | 00.00% | View details for Lifesci Capital rating of KinderCare Learning Companies (NYSE:KLC) on 11/13/2025 |
SRZN Surrozen | $19.45
-2.9% | 11/13/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Surrozen (NASDAQ:SRZN) on 11/13/2025 |
AMLX Amylyx Pharmaceuticals | $32.09
-1.0% | 10/27/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Amylyx Pharmaceuticals (NASDAQ:AMLX) on 10/27/2025 |
KOD Kodiak Sciences | $32.87
-2.7% | 10/23/2025 | | Initiated Coverage | $40.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Kodiak Sciences (NASDAQ:KOD) on 10/23/2025 |
CADL Candel Therapeutics | $11.33
-6.9% | 10/21/2025 | | Initiated Coverage | $16.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Candel Therapeutics (NASDAQ:CADL) on 10/21/2025 |
DFTX Definium Therapeutics | $37.73
-0.7% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Definium Therapeutics (NASDAQ:DFTX) on 10/14/2025 |
DYN Dyne Therapeutics | $18.42
-4.0% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 10/14/2025 |
SVRA Savara | $5.32
-1.7% | 10/14/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Savara (NASDAQ:SVRA) on 10/14/2025 |
CMPX Compass Therapeutics | $2.05
-6.0% | 10/6/2025 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Compass Therapeutics (NASDAQ:CMPX) on 10/6/2025 |
KALA KALA BIO | $0.56
+1.1% | 9/29/2025 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/29/2025 |
GPCR Structure Therapeutics | $39.55
-4.1% | 9/8/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Structure Therapeutics (NASDAQ:GPCR) on 9/8/2025 |
AQST Aquestive Therapeutics | $4.99
-3.1% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aquestive Therapeutics (NASDAQ:AQST) on 9/3/2025 |
KALA KALA BIO | $0.56
+1.1% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of KALA BIO (NASDAQ:KALA) on 9/3/2025 |
PRAX Praxis Precision Medicines | $338.57
-1.9% | 9/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 9/3/2025 |
RVMD Revolution Medicines | $203.35
-2.1% | 8/18/2025 | | Initiated Coverage | $80.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Revolution Medicines (NASDAQ:RVMD) on 8/18/2025 |
PVLA Palvella Therapeutics | $150.39
-0.6% | 8/4/2025 | | Initiated Coverage | $90.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 8/4/2025 |
YARW Yarrow Bioscience | $28.44
-2.3% | 7/30/2025 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of Yarrow Bioscience (NASDAQ:YARW) on 7/30/2025 |
ABVX Abivax | $115.95
-2.9% | 7/23/2025 | | Boost Price Target | $45.00 ➝ $101.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Abivax (NASDAQ:ABVX) on 7/23/2025 |
CATX Perspective Therapeutics | $2.77
-7.4% | 7/12/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 7/12/2025 |
CRBP Corbus Pharmaceuticals | $8.24
-7.0% | 7/12/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 7/12/2025 |
DBVT DBV Technologies | $12.97
-3.5% | 6/26/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of DBV Technologies (NASDAQ:DBVT) on 6/26/2025 |
CBIO Crescent Biopharma | $19.46
-2.7% | 6/18/2025 | | Upgrade | $22.00 | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Crescent Biopharma (NASDAQ:CBIO) on 6/18/2025 |
TECX Tectonic Therapeutic | $28.61
-6.1% | 6/6/2025 | | Initiated Coverage | $87.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/6/2025 |
TECX Tectonic Therapeutic | $28.61
-6.1% | 6/5/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Tectonic Therapeutic (NASDAQ:TECX) on 6/5/2025 |
SRRK Scholar Rock | $55.67
+1.9% | 6/3/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Scholar Rock (NASDAQ:SRRK) on 6/3/2025 |
GLUE Monte Rosa Therapeutics | $14.32
+0.4% | 3/12/2025 | | Initiated Coverage | $19.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Monte Rosa Therapeutics (NASDAQ:GLUE) on 3/12/2025 |
IMNM Immunome | $24.97
-4.4% | 3/11/2025 | | Initiated Coverage | $20.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Immunome (NASDAQ:IMNM) on 3/11/2025 |
MOLN Molecular Partners | $4.19
-3.8% | 3/11/2025 | | Initiated Coverage | $12.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Molecular Partners (NASDAQ:MOLN) on 3/11/2025 |
TARA Protara Therapeutics | $3.79
-1.0% | 3/11/2025 | | Initiated Coverage | $22.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Protara Therapeutics (NASDAQ:TARA) on 3/11/2025 |
ZYME Zymeworks | $26.43
-2.7% | 3/11/2025 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Zymeworks (NASDAQ:ZYME) on 3/11/2025 |
CATX Perspective Therapeutics | $2.77
-7.4% | 3/6/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Perspective Therapeutics (NYSEAMERICAN:CATX) on 3/6/2025 |
AURA Aura Biosciences | $6.99
-2.9% | 1/31/2025 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 1/31/2025 |
JANX Janux Therapeutics | $17.68
-8.5% | 12/27/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Janux Therapeutics (NASDAQ:JANX) on 12/27/2024 |
MREO Mereo BioPharma Group | $0.24
+0.9% | 12/24/2024 | | Initiated Coverage | $10.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/24/2024 |
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain. Get the name and ticker of Louis Navellier's #1 AI stock free |
MREO Mereo BioPharma Group | $0.24
+0.9% | 12/23/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Mereo BioPharma Group (NASDAQ:MREO) on 12/23/2024 |
KURA Kura Oncology | $11.57
-4.3% | 10/22/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Kura Oncology (NASDAQ:KURA) on 10/22/2024 |
OKUR OnKure Therapeutics | $3.27
-3.3% | 10/10/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of OnKure Therapeutics (NASDAQ:OKUR) on 10/10/2024 |
LQDA Liquidia | $67.85
-1.8% | 10/3/2024 | | Initiated Coverage | $30.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/3/2024 |
LQDA Liquidia | $67.85
-1.8% | 10/2/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Liquidia (NASDAQ:LQDA) on 10/2/2024 |
ORKA Oruka Therapeutics | $91.65
+0.2% | 9/16/2024 | | Initiated Coverage | $41.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Oruka Therapeutics (NASDAQ:ORKA) on 9/16/2024 |
AURA Aura Biosciences | $6.99
-2.9% | 9/9/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Aura Biosciences (NASDAQ:AURA) on 9/9/2024 |
CELC Celcuity | $85.49
-5.1% | 8/26/2024 | | Initiated Coverage | $27.00 | Outperform | 00.00% | View details for Lifesci Capital rating of Celcuity (NASDAQ:CELC) on 8/26/2024 |
CRBP Corbus Pharmaceuticals | $8.24
-7.0% | 8/21/2024 | | Upgrade | | Strong-Buy | 00.00% | View details for Lifesci Capital rating of Corbus Pharmaceuticals (NASDAQ:CRBP) on 8/21/2024 |
ALXO ALX Oncology | $1.90
+3.3% | 7/31/2024 | | Downgrade | | Strong-Buy ➝ Hold | 00.00% | View details for Lifesci Capital rating of ALX Oncology (NASDAQ:ALXO) on 7/31/2024 |
